These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10386467)

  • 21. Cost comparison of parenteral estrogen and conventional hormonal treatment in patients with prostatic cancer.
    Henriksson P; Stege R
    Int J Technol Assess Health Care; 1991; 7(2):220-5. PubMed ID: 1907600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of platelet aggregation caused by estrogen treatment in patients with carcinoma of the prostate.
    Eisen M; Napp HE; Vock R
    J Urol; 1975 Jul; 114(1):93-7. PubMed ID: 1142508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of parenteral estrogen versus orchiectomy on blood coagulation and fibrinolysis in prostatic cancer patients.
    Aro J; Haapiainen R; Rasi V; Rannikko S; Alfthan O
    Eur Urol; 1990; 17(2):161-5. PubMed ID: 2178941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A high pretreatment plasma oestradiol level is associated with a low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer.
    Mikkola AK; Aro JL; Rannikko AS; Ruutu ML;
    BJU Int; 2008 May; 101(9):1090-5. PubMed ID: 18070186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
    Spetz AC; Hammar M; Lindberg B; Spångberg A; Varenhorst E;
    J Urol; 2001 Aug; 166(2):517-20. PubMed ID: 11458057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.
    Hedlund PO; Johansson R; Damber JE; Hagerman I; Henriksson P; Iversen P; Klarskov P; Mogensen P; Rasmussen F; Varenhorst E;
    Scand J Urol Nephrol; 2011 Nov; 45(5):346-53. PubMed ID: 21627403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group.
    Aro JL; Haapiainen RK; Rannikko SA; Alfthan OS
    Br J Urol; 1989 May; 63(5):512-4. PubMed ID: 2659136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
    Aro J; Ruutu M; Juusela H; Hansson E; Permi J
    Ann Chir Gynaecol Suppl; 1993; 206():5-8. PubMed ID: 8291869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma.
    Henriksson P; Blombäck M; Eriksson A; Stege R; Carlström K
    Br J Urol; 1990 Mar; 65(3):282-5. PubMed ID: 2110842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacology of polyestradiol phosphate.
    Gunnarsson PO; Norlén BJ
    Prostate; 1988; 13(4):299-304. PubMed ID: 3217277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of orchidectomy performed after cessation of estrogen therapy on serum testosterone concentrations in patients with prostatic carcinoma.
    Tomić R; Damber JE
    Urol Int; 1987; 42(6):441-4. PubMed ID: 3129850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer.
    Henriksson P; Blombäck M; Bratt G; Edhag O; Eriksson A; Vesterqvist O
    Med Oncol Tumor Pharmacother; 1989; 6(3):219-25. PubMed ID: 2515399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary orchiectomy versus estrogen therapy in advanced prostatic cancer--a randomized study: results after 7 to 10 years of followup.
    Johansson JE; Andersson SO; Holmberg L; Bergström R
    J Urol; 1991 Mar; 145(3):519-22; discussion 522-3. PubMed ID: 1997702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status].
    Stege R; Carlström K; Hedlund PO; Pousette A; von Schoultz B; Henriksson P
    Urologe A; 1995 Sep; 34(5):398-403. PubMed ID: 7483157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Parenteral estrogen--a safe therapeutic alternative in prostatic cancer seen from the cardiovascular point of view?].
    Henriksson P; Stege R; Collste L; Pousette A; Von Schoultz B; Carlström K
    Lakartidningen; 1992 Oct; 89(42):3493-4, 3497. PubMed ID: 1435052
    [No Abstract]   [Full Text] [Related]  

  • 37. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
    Lundgren R; Nordle O; Josefsson K
    J Urol; 1995 May; 153(5):1580-6. PubMed ID: 7714978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Steroid-sensitive proteins, growth hormone and somatomedin C in prostatic cancer: effects of parenteral and oral estrogen therapy.
    Stege R; Fröhlander N; Carlström K; Pousette A; von Schoultz B
    Prostate; 1987; 10(4):333-8. PubMed ID: 2440014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate.
    Mikkola A; Aro J; Rannikko S; Oksanen H; Ruutu M;
    Scand J Urol Nephrol; 2005; 39(4):294-300. PubMed ID: 16261661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study.
    Lundgren R; Sundin T; Colleen S; Lindstedt E; Wadström L; Carlsson S; Hellsten S; Pompeius R; Holmquist B; Nilsson T
    Scand J Urol Nephrol; 1986; 20(2):101-5. PubMed ID: 3529368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.